Only 54 percent of the more than 7,800 supplement and research-compound brands assessed in a 2026 industry analysis carry verified third-party testing credentials. In a research supply category built almost entirely on trust between supplier and buyer, that figure means nearly half the market is still asking researchers to take purity and identity claims on faith.
The Market Context: A Testing Infrastructure Under Growing Demand
The global peptide synthesis market reached approximately 1.9 billion USD in 2026 and is projected to grow to 2.59 billion USD by 2031. The broader pharmaceutical analytical testing outsourcing market was valued at 8.3 billion USD in 2023 and is projected to grow at a CAGR of 8.4 percent from 2024 through 2030. The global LC-MS market was estimated at roughly 8.17 billion USD in 2026 and is projected to grow at a CAGR of around 12 percent to reach 18.02 billion USD by 2033.
What Third-Party Testing Actually Measures
HPLC remains the primary method for assessing purity, separating a sample’s components and showing the target peptide as a dominant peak. Mass spectrometry, frequently paired with HPLC as LC-MS, confirms identity rather than purity, measuring the mass-to-charge ratio of ionized molecules.
In-House vs Independent Verification: Why the Distinction Is Not Cosmetic
An in-house lab is paid by, and reports to, the same entity whose product it is testing. An independent third-party lab has no financial relationship tied to the outcome of the test. Independent labs are also more likely to hold formal accreditation, such as ISO/IEC 17025.
The Accreditation Gap
A certificate of analysis from an independent lab is a meaningfully stronger signal than an internal one, but a COA alone does not confirm the lab issuing it is itself accredited to a recognized standard. The laboratory proficiency testing market was valued at roughly 1.68 to 2.8 billion USD in 2026.
How Researchers Can Verify a Testing Claim
The COA should be batch- or lot-specific, not a generic document reused across every order. The issuing lab should be named and, ideally, independently searchable in a public accreditation body registry.
How It Works in Practice
The pattern among more rigorous operators follows a consistent shape: batches are tested by an outside lab before or shortly after production, and the resulting COA is tied to a specific lot number. Bluum Peptides is one supplier that supports batch-specific third-party verification requests as part of its standard process, allowing researchers to request lab documentation tied to the particular lot they have received.
Where the Industry Is Trending
A 2021 survey found that more than 77 percent of Americans said they prefer purchasing supplements certified by a third party. Growth trajectories across pharmaceutical analytical testing outsourcing, LC-MS instrumentation demand, and proficiency testing infrastructure all point toward an industry building more testing capacity rather than less.
Conclusion
Third-party testing has moved from a differentiator to something closer to a baseline expectation. The distinction between an in-house quality claim and an independently verified one is a structural difference in who has an incentive to produce a favorable result.
This article is intended for research and informational purposes only and does not constitute guidance for human use, diagnostic application, or therapeutic administration of any peptide compound.